2,6-Dimethyl-4-(1,3,4-oxadiazol-2-yl)quinoline.

The title compound, C(13)H(11)N(3)O, a potential chemotherapeutic agent, contains a essential planar [maximum deviation = 0.0144 (14) Å] quinoline moiety. The quinoline ring system and the five-membered heterocycle form a dihedral angle of 7.

4-Allyl-3-(2-methyl-4-quinol-yl)-1H-1,2,4-triazole-5(4H)-thione.

In the title compound, C(15)H(14)N(4)S, the quinoline and triazole rings form a dihedral angle of 41.48 (7)°. In the crystal, adjacent mol-ecules are linked by N-H⋯N hydrogen bonds, forming chains along [100].

Methyl 4-methyl-2-oxo-1,2,5,6-tetra-hydro-4H-pyrrolo[3,2,1-ij]quinoline-6-carboxyl-ate.

In the title mol-ecule, C(14)H(15)NO(3), the six-membered heterocyclic ring exhibits an envelope conformation. In the crystal, C-H⋯π inter-actions link the mol-ecules into centrosymmetric dimers, and weak inter-molecular C-H⋯O hydrogen bonds link these dimers into columns propagated along [100].

[Catalytic autoantibodies in autoimmune myocarditis: clinical and pathogenetic implications].

Aim: To evaluate pathogenetic and clinical significance of autoantibodies (AAB) with catalytic activity in the serum of patients with autoimmune myocarditis (AM).

Material And Methods: The study was made on the sera from 99 patients with AM of different course: malignant, benign, myocardiosclerosis (MCS). In addition to standard immunological parameters, the study was made of serum levels of anticardiomyosine-antiCM (protabzymes) and anti-DNA (DNA-abzymes) of AAB.